About
CILAHEART T is a combination medication containing Cilnidipine, a dual L-type and N-type calcium channel blocker, and Telmisartan, an angiotensin II receptor blocker (ARB). Cilnidipine reduces blood pressure by inhibiting calcium influx into vascular smooth muscle cells, leading to vasodilation, and uniquely, by blocking N-type channels, which may attenuate sympathetic overactivity. Telmisartan works by selectively blocking the AT1 receptor, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II.
This combination provides comprehensive blood pressure control by targeting different physiological pathways involved in hypertension. The synergistic action of a CCB and an ARB often results in a more pronounced antihypertensive effect than either drug alone, making it suitable for patients who require more aggressive blood pressure management. It helps to reduce the risk of cardiovascular events and improve overall patient outcomes.
Uses
- Treatment of essential hypertension.
- When blood pressure is not controlled by monotherapy.
- To achieve optimal blood pressure targets.
- Reduction of cardiovascular risk in hypertensive patients.
Directions For Use
Take one tablet orally once daily, preferably at the same time each day, with or without food. Follow your doctor's instructions.
Benefits
- Effective and sustained blood pressure reduction.
- Dual mechanism of action for comprehensive control.
- May reduce sympathetic overactivity (due to Cilnidipine).
- Low incidence of cough compared to ACE inhibitors.
- Reduces risk of cardiovascular events.
- Convenient once-daily dosing.
Side Effects
- Dizziness
- Headache
- Fatigue
- Flushing
- Ankle edema
- Nausea
- Diarrhea
- Hypotension
- Hyperkalemia
- Renal dysfunction
- Back pain
- Upper respiratory tract infection
Safety Measures
- Alcohol - Alcohol may increase the hypotensive effects of this combination, leading to enhanced dizziness or lightheadedness. Limit alcohol intake.
- Pregnancy - This medication is contraindicated during pregnancy, especially in the second and third trimesters, due to the risk of fetal harm.
- Breastfeeding - Both Cilnidipine and Telmisartan may be excreted in breast milk. It is generally not recommended during breastfeeding.
- Liver - Use with caution in patients with hepatic impairment; dosage adjustments may be necessary.
- Kidney - Use with caution in patients with renal impairment; regular monitoring of kidney function and serum potassium is advised.
- Lung - Generally safe for use in patients with lung conditions, as it does not typically cause respiratory side effects.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!